DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

H.C. Wainwright Maintains Buy on Kindred Biosciences, Lowers Price Target to $9

H.C. Wainwright analyst Swayampakula Ramakanth maintains Kindred Biosciences (NASDAQ:KIN) with a Buy and lowers the price target from $16 to $9.

Benzinga · 03/17/2020 11:29

H.C. Wainwright analyst Swayampakula Ramakanth maintains Kindred Biosciences (NASDAQ:KIN) with a Buy and lowers the price target from $16 to $9.